HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Pantina Cosmetics Mass Market Debut Slated For January

This article was originally published in The Rose Sheet

Executive Summary

Pantina cosmetics will debut in January in mass market retailers including Duane Reade, Brooks, Eckerd, CVS, Longs and Albertson's, the company announced

You may also be interested in...

NACDS Marketplace In Brief

Clearasil: Clearasil Ultra line will be extended with Acne Scar Care System, a regimen "specially formulated to reduce the appearance of scars leftover from acne and help prevent new ones from forming," according to Boots Healthcare International. The range was presented at the National Association of Chain Drug Stores Marketplace conference in New Orleans June 4-7. Targeted to consumers ages 18-24, line features three products, including Exfoliating Acne Wash, which contains 2% salicylic acid and a dual exfoliator that "stimulates skin renewal." Protecting Day Lotion with SPF 15 "protects healing skin" and contains 7.5% octinoxate and 2.5% avobenzone, while Night Repair Lotion "improves the appearance of scars." System, which provides 30-45 days of treatment, will carry an SRP of $19.99-$24.99. Acne Scar Care System will launch in the U.S. in July and will be supported with national print ads...

Hologic's Adiana Permanent Birth Control Device Takes On Conceptus' Essure

Adiana uses a polymer matrix insert to block the fallopian tubes instead of a metal coil, offering a benefit over Essure, which carries a perforation risk on implantation, Hologic exec says.

MADIT-CRT Data Support Expanded Cardiac Resynchronization Market

The results show that cardiac resynchronization defibrillators "slow the progression of heart failure in asymptomatic and mildly symptomatic patients," potentially expanding the market by $600 million.



Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts